[PDF/Direct View] Domestic bio and pharmaceutical stocks are continuing a trend of differentiation based on clinical development achievements and expectations for technology exports. With expectations of global interest rate cuts and reviving investment sentiment for growth stocks, attention is refocusing on the biotech sector.

In the morning stock market on the 11th, HLB traded at 48,750 won, up 0.52% from the previous trading day. It showed a steady trend, rising to 49,000 won during the session, but affiliate stocks generally showed weakness. HLB Life Sciences fell 2.10%, HLB Global 1.87%, HLB Innovation 1.88%, and HLB Pharmaceutical 1.17%.

Meanwhile, among large-cap bio stocks, Alteogen led the rally, surging 8.57% to 342,000 won. ABL Bio also recorded a 1.55% increase to 91,600 won, and Peptron traded at 246,500 won, up 1.86%, attracting investors' attention.

However, the trends of large bio stocks were mixed. Samsung Biologics traded at 1,271,000 won, down 2.08%, and Celltrion fell 1.49% to 164,800 won. Olix also declined 2.52% as profit-taking sell-offs emerged.

The industry analyzes that as global pharmaceutical companies continue to compete to secure new drug pipelines, expectations for technology exports by domestic bio companies are rising. In particular, as research and development achievements continue in areas such as anticancer drugs, obesity treatments, and antibody drugs, movements to re-evaluate corporate value are also emerging.

The market evaluates that recent expectations for easing geopolitical tensions surrounding the US and Iran are partially recovering the preference for risk assets. Analysts suggest that the biotech sector, which has a high proportion of growth stocks, could also be affected by this improvement in investment sentiment.

The securities industry advises that when it comes to bio companies, investors should approach them based on fundamental growth drivers—such as clinical results, technology export contracts, and new drug approval schedules—rather than short-term stock price volatility. In particular, the R&D progress of major bio companies, including HLB, is cited as a key variable that will dictate future stock price trends.

[This article was written with the assistance of AI. This article is intended to provide information for reference in making investment decisions and does not recommend the purchase or sale of specific stocks. Any losses resulting from stock investments are borne by the investor, and investment decisions must be made after sufficient review and under one's own responsibility.]